Spinal Cord Injury – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23107IDB-L5

Select Item

Empower your strategies with our Spinal Cord Injury – Drugs In Development, 2024 report and make more profitable business decisions.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida, or Friedreich’s ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head, or back; paralysis in any part of the body; numbness, tingling, or loss of sensation in the hands, fingers, feet, or toes; loss of bladder or bowel control; difficulty in walking; and impaired breathing after injury.

The Spinal Cord Injury drugs in development market research report provide comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Spinal Cord Injury
Key Targets
· Reticulon 4 ; Receptor Type Tyrosine Protein Phosphatase S; Repulsive Guidance Molecule A; Prolow Density Lipoprotein Receptor Related Protein 1; Phospholipase A2; Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN; Solute Carrier Family 12 Member 5; Fidgetin Like Protein 2; Free Radical; and Glutamate Ionotropic Receptor AMPA Type Subunit
Key Mechanisms of Action
· Reticulon 4 Inhibitor; Receptor Type Tyrosine Protein Phosphatase S Inhibitor; Repulsive Guidance Molecule A Inhibitor; Prolow Density Lipoprotein Receptor Related Protein 1 Antagonist; Solute Carrier Family 12 Member 5 Activator; Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN Inhibitor; Phospholipase A2 Inhibitor; Fidgetin Like Protein 2 Inhibitor; Free Radical Scavenger; and Gap Junction Alpha 1 Protein Inhibitor
Key Routes of Administration
· Intravenous; Parenteral; Oral; Intrathecal; Subcutaneous; Topical; Intravenous Drip; Nasal; Intracerebral; and Intramuscular
Key Molecule Types
· Cell Therapy; Small Molecule; Monoclonal Antibody; Synthetic Peptide; Gene Therapy; Fusion Protein; Antisense RNAi Oligonucleotide; Peptide; Biologic; and Antibody
Major Companies
· AXONIS Therapeutics Inc; Axoltis Pharma SAS; Drexel University; Kidswell Bio Corp; MicroCures Inc; Novoron Bioscience Inc; NervGen Pharma Corp; SanBio Co Ltd; Shanghai Angecon Biotechnology Co Ltd; and S.Biomedics Co Ltd

Scope

  • Therapeutics in Development: Covering 103 molecules, with 87 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Spinal Cord Injury therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Spinal Cord Injury pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Spinal Cord Injury treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

9 Meters Biopharma Inc
AbbVie Inc
AlaMab Therapeutics Inc
Aposcience AG
Asha Therapeutics LLC
AstraZeneca Plc
Athersys Inc
Aviceda Therapeutics Inc
Axoltis Pharma SAS
Axoneural Therapeutics Inc
AXONIS Therapeutics Inc
BioAxone BioSciences Inc
Biostar Stem Cell Research Institute
Brainxell Therapeutics Inc
Case Western Reserve University
Cellatoz Therapeutics Inc
Chengdu Shiliankangjian Biotechnology Co Ltd
Cristalia Produtos Quimicos Farmaceuticos Ltda
CSL Ltd
Daewoong Pharmaceutical Co Ltd
DeckTherapeutics Inc
Drexel University
Elicio Therapeutics Inc
GABA Therapeutics Inc
Gene Therapy Research Institution Co Ltd
Genervon Biopharmaceuticals LLC
GNT Pharma Co Ltd
Guangzhou Cellprotek Pharmaceutical Co Ltd
Helixmith Co Ltd
Hemera Srl
Hemostemix Inc
Hibernaid Inc
Hope Biosciences LLC
Hopstem Biotechnology LLC
iCELL Biotechnology Co Ltd
Inteligex Inc
Kaneka Corp
Kidswell Bio Corp
King's College London
Kringle Pharma Inc
Life Sciences Institute
Lineage Cell Therapeutics Inc
Locate Bio Ltd
Mapreg SAS
Medinno Inc
MicroCures Inc
Mitsubishi Tanabe Pharma Corp
NervGen Pharma Corp
NeuExcell Therapeutics Inc
Neural Stem Cell Institute
Neurodawn Pharmaceutical Co Ltd
Neuroplast BV
NeuroSolv Therapeutics Ltd
New World Laboratories Inc
Nipro Corp
Novago Therapeutics AG
Novartis AG
Novoron Bioscience Inc
NuNerve Pty Ltd
NurExone Biologic Inc
Olatec Therapeutics LLC
Oligogen Inc
Pasteur Institute
PharmatrophiX Inc
Q Therapeutics Inc
Q32 Bio Inc
RE-Stem Biotech Co Ltd
ReNetX Bio
RespireRx Pharmaceuticals Inc
Rudacure Co Ltd
Rutgers The State University of New Jersey
S.Biomedics Co Ltd
SanBio Co Ltd
Shanghai Angecon Biotechnology Co Ltd
Stand Up Therapeutics Co Ltd
StemCyte Inc
Stemedica Cell Technologies Inc
Stemmatters Biotecnologia e Medicina Regenerativa SA
Stony Brook University
Sumitomo Pharma Co Ltd
TechnoPhage SA
The Cleveland Clinic Foundation
TNAX Biopharma Corp
Truvitech LLC
Tumorend LLC
University of California Los Angeles
University of California San Diego
University of Miami
University of North Carolina at Chapel Hill
VersaPeutics Inc
Weizmann Institute of Science
YiPSCELL Co Ltd
ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Spinal Cord Injury reports
Pharmaceuticals
New
Global M&A Deals in H1 2026 - Top Themes by…
$495 | August 2026
Pharmaceuticals
New
Pharmaceutical Drug Development Annual Review 2025
$1,200 | August 2026
Pharmaceuticals
New
Modality Intelligence - From Pipeline to Capital: Strategic Intelligence
$3,450 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Spinal Cord Injury – Drugs In Development, 2024 in real time.

  • Access a live Spinal Cord Injury – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more